Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2022

06.11.2021 | Research Article

Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients

verfasst von: A. W. Mao, H. Barck, J. Young, A. Paley, J. -H. Mao, H. Chang

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognosis of breast cancer (BC) patients differs considerably and identifying reliable prognostic biomarker(s) is imperative. With evidence that the microbiome plays a critical role in the response to cancer therapies, we aimed to identify a cancer microbiome signature for predicting the prognosis of BC patients.

Methods

The TCGA BC microbiome data (TCGA-BRCA-microbiome) was downloaded from cBioPortal. Univariate and multivariate Cox regression analyses were used to examine association of microbial abundance with overall survival (OS) and to identify a microbial signature for creating a prognostic scoring model. The performance of the scoring model was assessed by the area under the ROC curve (AUC). Nomograms using the microbial signature, clinical factors, and molecular subtypes were established to predict OS and progression-free survival (PFS).

Results

Among 1406 genera, the abundances of 94 genera were significantly associated with BC patient OS in TCGA-BRCA-microbiome dataset. From that set we identified a 15-microbe prognostic signature and developed a 15-microbial abundance prognostic scoring (MAPS) model. Patients in low-risk group significantly prolong OS and PFS as compared to those in high-risk group. The time-dependent ROC curves with MAPS showed good predictive efficacy both in OS and PFS. Moreover, MAPS is an independent prognostic factor for OS and PFS over clinical factors and PAM50-based molecular subtypes and superior to the previously published 12-gene signature. The integration of MAPS into nomograms significantly improved prognosis prediction.

Conclusion

MAPS was successfully established to have independent prognostic value, and our study provides a new avenue for developing prognostic biomarkers by microbiome profiling.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.CrossRef Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.CrossRef
2.
Zurück zum Zitat Norum JH, Andersen K, Sorlie T. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. Br J Surg. 2014;101:925–38.CrossRef Norum JH, Andersen K, Sorlie T. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. Br J Surg. 2014;101:925–38.CrossRef
3.
Zurück zum Zitat Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and cancer. Genes Dis. 2021;8:581–9.CrossRef Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and cancer. Genes Dis. 2021;8:581–9.CrossRef
4.
Zurück zum Zitat Parida S, Sharma D. The microbiome-estrogen connection and breast cancer risk. Cells. 2019;8:1642.CrossRef Parida S, Sharma D. The microbiome-estrogen connection and breast cancer risk. Cells. 2019;8:1642.CrossRef
5.
Zurück zum Zitat Plaza-Diaz J, Alvarez-Mercado AI, Ruiz-Marin CM, et al. Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case–control clinical study. BMC Cancer. 2019;19:495.CrossRef Plaza-Diaz J, Alvarez-Mercado AI, Ruiz-Marin CM, et al. Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case–control clinical study. BMC Cancer. 2019;19:495.CrossRef
6.
Zurück zum Zitat Buchta Rosean C, Bostic RR, Ferey JCM, et al. Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 2019;79:3662–75.CrossRef Buchta Rosean C, Bostic RR, Ferey JCM, et al. Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 2019;79:3662–75.CrossRef
7.
Zurück zum Zitat Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951.CrossRef Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951.CrossRef
8.
Zurück zum Zitat Smith A, Pierre JF, Makowski L, et al. Distinct microbial communities that differ by race, stage, or breast-tumor subtype in breast tissues of non-Hispanic black and non-Hispanic white women. Sci Rep. 2019;9:11940.CrossRef Smith A, Pierre JF, Makowski L, et al. Distinct microbial communities that differ by race, stage, or breast-tumor subtype in breast tissues of non-Hispanic black and non-Hispanic white women. Sci Rep. 2019;9:11940.CrossRef
9.
Zurück zum Zitat Tzeng A, Sangwan N, Jia M, et al. Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Med. 2021;13:60.CrossRef Tzeng A, Sangwan N, Jia M, et al. Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Med. 2021;13:60.CrossRef
10.
Zurück zum Zitat Shvets YV, Lukianova NY, Chekhun VF. Human microbiota and effectiveness of cancer chemotherapy. Exp Oncol. 2020;42:82–93.PubMed Shvets YV, Lukianova NY, Chekhun VF. Human microbiota and effectiveness of cancer chemotherapy. Exp Oncol. 2020;42:82–93.PubMed
11.
Zurück zum Zitat Tonneau M, Elkrief A, Pasquier D, et al. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: a systematic review. Radiother Oncol. 2021;156:1–9.CrossRef Tonneau M, Elkrief A, Pasquier D, et al. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: a systematic review. Radiother Oncol. 2021;156:1–9.CrossRef
12.
Zurück zum Zitat Pham F, Moinard-Butot F, Coutzac C, Chaput N. Cancer and immunotherapy: a role for microbiota composition. Eur J Cancer. 2021;155:145–54.CrossRef Pham F, Moinard-Butot F, Coutzac C, Chaput N. Cancer and immunotherapy: a role for microbiota composition. Eur J Cancer. 2021;155:145–54.CrossRef
13.
Zurück zum Zitat Chiba A, Bawaneh A, Velazquez C, et al. Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Mol Cancer Res. 2020;18:130–9.CrossRef Chiba A, Bawaneh A, Velazquez C, et al. Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Mol Cancer Res. 2020;18:130–9.CrossRef
14.
Zurück zum Zitat Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70.CrossRef Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70.CrossRef
15.
Zurück zum Zitat Shiao SL, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell. 2021;39:1202.CrossRef Shiao SL, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell. 2021;39:1202.CrossRef
16.
Zurück zum Zitat Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.CrossRef Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.CrossRef
18.
Zurück zum Zitat Poore GD, Kopylova E, Zhu Q, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567–74.CrossRef Poore GD, Kopylova E, Zhu Q, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567–74.CrossRef
19.
Zurück zum Zitat Mao XY, Lee MJ, Zhu J, et al. Genome-wide screen identifies a novel prognostic signature for breast cancer survival. Oncotarget. 2017;8:14003–16.CrossRef Mao XY, Lee MJ, Zhu J, et al. Genome-wide screen identifies a novel prognostic signature for breast cancer survival. Oncotarget. 2017;8:14003–16.CrossRef
20.
Zurück zum Zitat Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56–73.CrossRef Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56–73.CrossRef
21.
Zurück zum Zitat Schick J, Ritchie RP, Restini C. Breast cancer therapeutics and biomarkers: past, present, and future approaches. Breast Cancer (Auckl). 2021;15:1178223421995854. Schick J, Ritchie RP, Restini C. Breast cancer therapeutics and biomarkers: past, present, and future approaches. Breast Cancer (Auckl). 2021;15:1178223421995854.
22.
Zurück zum Zitat Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018;67:1984–94.CrossRef Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018;67:1984–94.CrossRef
23.
Zurück zum Zitat Yu AI, Zhao L, Eaton KA, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. 2020;31:107471.CrossRef Yu AI, Zhao L, Eaton KA, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. 2020;31:107471.CrossRef
24.
Zurück zum Zitat Zhu G, Su H, Johnson CH, et al. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. Eur J Cancer. 2021;151:25–34.CrossRef Zhu G, Su H, Johnson CH, et al. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. Eur J Cancer. 2021;151:25–34.CrossRef
25.
Zurück zum Zitat Demay J, Halary S, Knittel-Obrecht A, et al. Anti-inflammatory, antioxidant, and wound-healing properties of cyanobacteria from thermal mud of Balaruc-Les-Bains, France: a multi-approach study. Biomolecules. 2020;11:28.CrossRef Demay J, Halary S, Knittel-Obrecht A, et al. Anti-inflammatory, antioxidant, and wound-healing properties of cyanobacteria from thermal mud of Balaruc-Les-Bains, France: a multi-approach study. Biomolecules. 2020;11:28.CrossRef
26.
Zurück zum Zitat Matsuoka T, Yashiro M, Sawada T, et al. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor. Anticancer Res. 2000;20:4331–8.PubMed Matsuoka T, Yashiro M, Sawada T, et al. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor. Anticancer Res. 2000;20:4331–8.PubMed
27.
Zurück zum Zitat Chen X, Gu Y, Singh K, et al. Maduramicin inhibits proliferation and induces apoptosis in myoblast cells. PLOS ONE. 2014;9:e115652.CrossRef Chen X, Gu Y, Singh K, et al. Maduramicin inhibits proliferation and induces apoptosis in myoblast cells. PLOS ONE. 2014;9:e115652.CrossRef
28.
Zurück zum Zitat Shaaban KA, Elshahawi SI, Wang X, et al. Cytotoxic indolocarbazoles from actinomadura melliaura ATCC 39691. J Nat Prod. 2015;78:1723–9.CrossRef Shaaban KA, Elshahawi SI, Wang X, et al. Cytotoxic indolocarbazoles from actinomadura melliaura ATCC 39691. J Nat Prod. 2015;78:1723–9.CrossRef
29.
Zurück zum Zitat Howard MT, Sandman K, Reeve JN, Griffith JD. HMf, a histone-related protein from the hyperthermophilic archaeon methanothermus fervidus, binds preferentially to DNA containing phased tracts of adenines. J Bacteriol. 1992;174:7864–7.CrossRef Howard MT, Sandman K, Reeve JN, Griffith JD. HMf, a histone-related protein from the hyperthermophilic archaeon methanothermus fervidus, binds preferentially to DNA containing phased tracts of adenines. J Bacteriol. 1992;174:7864–7.CrossRef
30.
Zurück zum Zitat Sandman K, Krzycki JA, Dobrinski B, et al. HMf, a DNA-binding protein isolated from the hyperthermophilic archaeon methanothermus fervidus, is most closely related to histones. Proc Natl Acad Sci USA. 1990;87:5788–91.CrossRef Sandman K, Krzycki JA, Dobrinski B, et al. HMf, a DNA-binding protein isolated from the hyperthermophilic archaeon methanothermus fervidus, is most closely related to histones. Proc Natl Acad Sci USA. 1990;87:5788–91.CrossRef
Metadaten
Titel
Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients
verfasst von
A. W. Mao
H. Barck
J. Young
A. Paley
J. -H. Mao
H. Chang
Publikationsdatum
06.11.2021
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02725-3

Weitere Artikel der Ausgabe 3/2022

Clinical and Translational Oncology 3/2022 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.